Northeast Pharmaceutical Group Co., Ltd. (Northeast Pharm, stock code: 000597) is a publicly listed company of Fangda Group. Founded in 1946 as Northeast General Pharmaceutical Factory, the company has assisted in the development of 52 pharmaceutical companies and the training of over 1300 management specialists across 19 cities in China. It is widely recognized as the cradle of China's national pharmaceutical industry.

Currently, Northeast Pharm's businesses encompass APIs, chemical preparations, pharmaceutical commerce, pharmaceutical engineering, and biopharmaceuticals. The company operates across pharmaceutical development, manufacturing, and distribution, with a workforce of over 7000 employees and total assets of 14.541 billion yuan. Its diverse product portfolio includes vitamins, anti-infectives, obstetric and gynecological drugs, gastrointestinal drugs, urinary system medications, antiviral drugs, drugs for cardiovascular and cerebrovascular diseases, painkillers and cough medicines, biological diagnosis, and healthcare services, as well as more than 400 APIs, pharmaceutical intermediates, and preparations. Notably, its featured products are sold in over 100 countries and regions.

Northeast Pharm prides itself on its robust product manufacturing system. It owns a 180,000㎡ preparation production center capable of producing 13.3 billion tablets/vials/capsules/bottles annually with its over 30 production lines; and the API production center, occupying 910,000㎡, is a role-model plant for smart manufacturing of bulk drugs and pharmaceutical intermediates in China, focusing on products such as vitamin C, L-carnitine, fosfomycin, piracetam, carboprost methylate, amantadine, sucralfate, berberine, and chloramphenicol. The company also extends its comprehensive services to downstream processing, giving it unrivaled competitive edge.

Recognized as a National Green Factory, the company's factory is equipped with the country's most advanced environmental solution that realizes all-round treatment of sewage, exhaust gas, noise, and solid waste. Its cutting-edge treatment system can process up to 40,000m³ API-contaminated wastewater daily, and its incinerators can handle 9000 tons of hazardous waste annually while meeting the EU standards for exhaust gas. It is also worth noting that the plant adopts technology to recycle waste from production into reusable resources.

Northeast Pharm operates with a comprehensive and functional quality management system, ensuring that its product quality complies with the latest standards from the EP, USP, JP, BP, ChP, and other major pharmacopeias. Many of its products have received approvals from international organizations such as the EDQM, FDA, MHLW Japan, BRC, Halal, and Kosher. Additionally, the company's featured products have successfully passed registration and quality reviews in countries and regions including the United States, Europe, Japan, Brazil, Russia and Poland.

Enterprise official website link：http://www.nepharm.com.cn/